Regarding the efficacy of downstream target inhibition, e.g. CCNE2 inhibitors, to overcome imatinib resistance, further studies are necessary to address the role of KMT2D in therapy resistant CML. This evidence concerns the gene KMT2D and chronic myelogenous leukemia, BCR-ABL1 positive.